Security key
50127T109
Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (KURA)
CUSIP: 50127T109
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 85,261,971
- Total 13F value
- $885,726,020
- Share change
- +1,465,396
- Put/Call ratio
- 70%
- SEC-reported price per share
- $10.39
- Number of holders
- 212
- Value change
- +$20,154,669
- Number of buys
- 131
- Number of sells
- 79
- Shares outstanding
- 88,321,513
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q4 2025
Institutions
212
Top holders
10
KURA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Kura Oncology, Inc. SEC filings
Kura Oncology, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 50127T109
Recent filing periods:
Ownership snapshot
Top reported holders of KURA - Kura Oncology, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
BlackRock, Inc.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 10%
13D/G row: BIOTECHNOLOGY VALUE FUND L P
Showing 1-6 of 15 holder rows.
Quick read
BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
BIOTECHNOLOGY VALUE FUND L P
10%
SUVRETTA CAPITAL MANAGEMENT, LLC
9.4%
BlackRock, Inc.
7.8%
ARMISTICE CAPITAL, LLC
7.1%
STATE STREET CORP
5.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$76,791,609
8,677,018 shares
|
+$24,465,506 | 30 Sep 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
13D/G
Company
|
9.4%
from 13D/G
|
$71,826,600
8,116,000 shares
|
— | 30 Sep 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.8%
from 13D/G
|
$84,208,945
9,515,135 shares
|
— | 30 Sep 2025 |
| ARMISTICE CAPITAL, LLC |
13F
13D/G
Company
|
7.1%
from 13D/G
|
$41,347,200
4,672,000 shares
|
— | 30 Sep 2025 |
| STATE STREET CORP |
13D/G
13F
STATE STREET CORPORATION · Company
|
5.7%
|
$45,218,095
4,931,090 shares
|
$0 | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
|
4.9%
|
$26,070,011
4,004,610 shares
|
$0 | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
212
Shares
85,261,971
Rows available
212
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
197
Q4 2025 holders
212
Holder diff
15
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend